As KRAS was implicated as a mutation in IPMN progression to PDAC, it is reasonable to suggest downstream results from KRAS mutation in PDAC may apply to its precursor, IPMN. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.